Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

被引：0
|
作者：
Michela Del Prete
François-Alexandre Buteau
Jean-Mathieu Beauregard
机构：
[1] Université Laval,Department of Radiology and Nuclear Medicine, and Cancer Research Center
[2] CHU de Québec – Université Laval,Department of Medical Imaging, and Oncology Branch of Research Center
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
Personalized; Peptide receptor radionuclide therapy; Lu-octreotate; Dosimetry; Neuroendocrine tumours;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1490 / 1500
页数：10
相关论文
共 50 条
  • [41] irtGPUMCD: a new GPU-calculated dosimetry code for 177Lu-octreotate radionuclide therapy of neuroendocrine tumors
    Montegiani, Jean-Francois
    Gaudin, Emilie
    Jackson, Price A.
    Beauregard, Jean-Mathieu
    Despres, Philippe
    MEDICAL PHYSICS, 2014, 41 (08) : 1 - 1
  • [42] Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
    W. A. van der Zwan
    T. Brabander
    B. L. R. Kam
    J. J. M. Teunissen
    R. A. Feelders
    J. Hofland
    E. P. Krenning
    W. W. de Herder
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 704 - 717
  • [43] Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
    van der Zwan, W. A.
    Brabander, T.
    Kam, B. L. R.
    Teunissen, J. J. M.
    Feelders, R. A.
    Hofland, J.
    Krenning, E. P.
    de Herder, W. W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (03) : 704 - 717
  • [44] Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors
    Calais, Phillipe J.
    Turner, J. Harvey
    ANNALS OF NUCLEAR MEDICINE, 2014, 28 (06) : 531 - 539
  • [45] Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
    Ezziddin, Samer
    Attassi, Mared
    Yong-Hing, Charlotte J.
    Ahmadzadehfar, Hojjat
    Willinek, Winfried
    Gruenwald, Frank
    Guhlke, Stefan
    Biersack, Hans-Juergen
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (02) : 183 - 190
  • [46] Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors
    Phillipe J. Calais
    J. Harvey Turner
    Annals of Nuclear Medicine, 2014, 28 : 531 - 539
  • [47] Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
    van Essen, Martijn
    Krenning, Eric P.
    Kam, Boen L. R.
    de Herder, Wouter W.
    Feelders, Richard A.
    Kwekkeboom, Dik J.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (03) : 383 - 390
  • [48] Lesion segmentation in Somatostatin Receptor Imaging with 111In-Pentetreotide and 177Lu-Octreotate for Response Monitoring of Neuroendocrine Tumors (net) treated with 177Lu-Octreotate
    Rotger Regi, A.
    Duran Barquero, C.
    Ardila Mantilla, J.
    Lozano Murgas, L.
    Perez-Pascual, R.
    Percovich, J.
    Garcia Centeno, R.
    Blanco Codesido, M.
    Perez Diaz, D.
    Alonso Farto, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S597 - S597
  • [49] Method dependence of absorbed dose calculation to the kidney in patients with neuroendocrine tumours receiving 177Lu-Octreotate therapy
    Sandstrom, Mattias
    Ilan, Ezgi
    Karlberg, Anna
    Garske-Roman, Ulrike
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [50] RADIATION SAFETY PRECAUTIONS WITH 177LU-OCTREOTATE THERAPY
    Browne, E.
    McKay, E.
    Smart, R. C.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 43 - 43
12345